Gabriela Cesarman Cesarman-Maus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6413626/publications.pdf

Version: 2024-02-01

20 papers	1,246 citations	840119 11 h-index	713013 21 g-index
21 all docs	21 docs citations	21 times ranked	1888 citing authors

#	Article	IF	Citations
1	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2022, 20, 409-421.	1.9	17
2	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. Journal of Thrombosis and Haemostasis, 2022, 20, 532-535.	1.9	7
3	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210829.	0.7	7
4	Venous Thromboembolism in Patients with Cancer Receiving Specialist Palliative Care. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210811.	0.7	2
5	Apixaban in lowâ€weight patients with cancerâ€associated thrombosis: A cross sectional study of drug levels. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 421-425.	1.0	3
6	Global reporting of pulmonary embolismâ€“related deaths in the World Health Organization mortality database: Vital registration data from 123Âcountries. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12520.	1.0	27
7	Cancerâ€associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. Internal Medicine Journal, 2020, 50, 366-370.	0.5	3
8	Oncolytic Viruses for Canine Cancer Treatment. Cancers, 2018, 10, 404.	1.7	31
9	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematology,the, 2018, 5, e289-e298.	2.2	219
10	Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. Journal of Clinical Oncology, 2017, 35, 2217-2218.	0.8	3
11	Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. Viruses, 2016, 8, 3.	1.5	15
12	Anticoagulant Proteins in a Population ofÂMexican Mestizo Donors. Annals of Vascular Surgery, 2015, 29, 222-226.	0.4	1
13	Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thrombosis Research, 2014, 133, 606-609.	0.8	14
14	The Annexin A2/S100A10 System in Health and Disease: Emerging Paradigms. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-13.	3.0	85
15	Thrombosis in multiple myeloma (MM). Hematology, 2012, 17, s177-s180.	0.7	40
16	Autoantibodies Against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis. Stroke, 2011, 42, 501-503.	1.0	32
17	Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood, 2006, 107, 4375-4382.	0.6	159
18	Molecular mechanisms of fibrinolysis. British Journal of Haematology, 2005, 129, 307-321.	1.2	570

#	Article	IF	Citations
19	Annexin checks in - Response to Waisman. British Journal of Haematology, 2005, 131, 554-556.	1.2	4
20	The Consular Program for Mexican Communities Abroad: A Source of Outreach for Health Workers. Journal of Transcultural Nursing, 2003, 14, 272-275.	0.6	4